Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of pirtobrutinib versus ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma
CTR20221907Phase 3Active
- Sponsor
- Loxo Oncology
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pirtobrutinib, ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Loxo Oncology. Started Sep 2022; status: active.
02
Drugs
pirtobrutinibibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20221907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221907.